Vaginal Atrophy Clinical Trial
Official title:
A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women
Verified date | February 2012 |
Source | Bionovo |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
To conduct a prospective, randomized, blinded, placebo controlled, dose escalation clinical trial in 4 cohorts of 10 postmenopausal women (total N=40) aged 45 to 65 years with at least one menopausal vaginal symptom, vaginal pH > 5.0 and > 20% parabasal vaginal epithelial cells.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | August 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 45 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Women between the ages of 45 and 65 2. Postmenopausal documented by: (a) at least one year of amenorrhea; (b) 6- 12 months of amenorrhea with serum FSH > 40 IU/ml; (c) 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, or (d) hysterectomy with serum FSH levels > 40 IU/ml. 3. Self-report at least one moderate to severe symptom of vulvar or vaginal atrophy from the following list: - Vaginal dryness (none, mild, moderate or severe) - Vaginal and/or vulvar discomfort (none, mild, moderate, severe) - Vaginal and/or vulvar irritation (none, mild, moderate, severe) - Vaginal itching (none, mild, moderate, severe) - Vaginal pain associated with sexual activity (none, mild, moderate or severe) 4. < 5% superficial cells on vaginal cytologic smear. 5. Vaginal pH >5.0 6. Willing to use an intravaginal cream containing Chinese herbs for the treatment of vaginal symptoms. 7. Provide informed consent. Exclusion Criteria: 1. History of breast, uterine or ovarian cancer or melanoma. 2. Abnormal mammogram or breast examination within the last 9 months suggestive of cancer. 3. Abnormal Pap smear or pelvic examination within the last 9 months suggestive of cancer. 4. Any uterine or vaginal bleeding within the six months prior to enrollment (except following the screening Pap smear). 5. Double-wall endometrial thickness that exceeds 5 mm measured on transvaginal ultrasound. 6. Pregnant or lactating. 7. Use of any vaginal moisturizer (Replens, KY Silk-E, Astroglide Silken Secret, Senselle) within 30 days of screening. 8. Use of any oral, transdermal, vaginal, or systemic estrogen or estrogen/progestin product within 30 days of screening. 9. Use of raloxifene, tamoxifen or aromatase inhibitors within 12 weeks of screening. 10. Current urinary tract infection (dipstick urinalysis positive for leukocyte estrace, nitrates or blood) 11. History of cardiovascular disease. 12. History of venous thromboembolic disease. 13. Use of another investigational agent within 12 weeks of screening. 14. Any medical or psychiatric condition that, in the investigator's opinion, would preclude the participant from completing questionnaires or measures, adhering to the protocol or completing the trial, including limited English literacy, severe illness, plans to move, substance abuse, significant psychiatric problems, or dementia. 15. No access to a telephone |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama, Birmingham | Birmingham | Alabama |
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Bionovo |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in self-reported symptoms of vaginal atrophy from baseline to 12 weeks | 4 and 12 weeks | No | |
Primary | Change in percent superficial vaginal epithelial cells from baseline 12 weeks | 4 and 12 weeks | No | |
Primary | Change in the pH of vaginal secretions from baseline to 12 weeks | 4 and 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06136975 -
Low-level Laser Therapy for Genitourinary Syndromes and Stress Urinary Incontinence
|
||
Recruiting |
NCT04081805 -
LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)
|
N/A | |
Completed |
NCT04039555 -
Clinical Study to Compare the Efficacy of Erbium-Yag Laser or CO2RE Intimate Laser With Sham (COER)
|
N/A | |
Active, not recruiting |
NCT02704741 -
Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments
|
N/A | |
Completed |
NCT01975129 -
A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin
|
Phase 2 | |
Completed |
NCT04735549 -
Vulvovaginal Atrophy Correction Using Neodymium Laser
|
N/A | |
Completed |
NCT04079218 -
Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
|
Phase 4 | |
Completed |
NCT03063684 -
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus
|
N/A | |
Recruiting |
NCT05953090 -
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
|
N/A | |
Not yet recruiting |
NCT05483634 -
Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause
|
||
Completed |
NCT04717245 -
Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment
|
N/A | |
Completed |
NCT02967510 -
Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy
|
Phase 2 | |
Completed |
NCT02937805 -
Effects of a Moisturizing Cream on Vaginal and Vulvar Mucous Membranes
|
N/A | |
Not yet recruiting |
NCT02571127 -
Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.
|
Phase 4 | |
Completed |
NCT00238732 -
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
|
Phase 3 | |
Completed |
NCT02413008 -
A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
|
Phase 2 | |
Completed |
NCT03493126 -
Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function
|
Phase 4 | |
Not yet recruiting |
NCT03238053 -
Laser Treatment of Genito-urinary Syndrome in Women
|
N/A | |
Terminated |
NCT01753102 -
Efficacy and Safety Of Spil's Estradiol Vaginal Tablet
|
Phase 3 | |
Terminated |
NCT05627791 -
Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman
|
Phase 2/Phase 3 |